NMC Case Report Journal
Online ISSN : 2188-4226
ISSN-L : 2188-4226
CASE REPORT
Safety of Adult-dose Clazosentan in an Adolescent with Aneurysmal Subarachnoid Hemorrhage: A Case Report
Teppei KAWABATA, Kakeru MORITA, Hiroaki SAGO, Yukimi WATANABE, Tasuku IMAI, Tomoyuki NODA, Hideki MAKI
著者情報
ジャーナル オープンアクセス HTML

2026 年 13 巻 p. 547-552

詳細
Abstract

Aneurysmal subarachnoid hemorrhage is extremely rare in children, and treatments for postoperative cerebral vasospasm and delayed cerebral ischemia have not yet been established. Clazosentan is a selective endothelin A receptor antagonist that inhibits symptomatic cerebral vasospasm onset in adults with aneurysmal subarachnoid hemorrhage. However, its administration in children is notably limited. This case report demonstrates the safety of clazosentan in early adolescent patients with aneurysmal subarachnoid hemorrhage. A 14-year-old male presented with a subarachnoid hemorrhage and intracerebral hematoma due to a ruptured saccular aneurysm at the right internal carotid artery terminus. After clipping and hematoma removal, clazosentan was administered at 10 mg/h (0.18 mg/kg/h) for 14 days from postoperative day 1 according to the adult dose. Clinical examination as well as postoperative magnetic resonance imaging and computed tomography angiography did not reveal a cerebral vasospasm or cerebral infarction. No adverse events such as hypotension, pulmonary edema, or cerebral edema were observed during the administration period. Thirty days after surgery, the patient was discharged with a modified Rankin Scale score of 1. This is the first study to demonstrate that an adult dose of clazosentan is safe for adolescent aneurysmal subarachnoid hemorrhage. This report suggests the potential clinical application of clazosentan in adolescents but does not indicate efficacy, and further studies involving additional cases are needed.

Introduction

Subarachnoid hemorrhage due to cerebral aneurysm rupture is extremely rare in children, and its complications and natural history are yet to be determined.1,2) Cerebral vasospasm and delayed cerebral ischemia (DCI) are major causes of poor prognosis with increased complications and mortality, making their prevention clinically crucial.1,3) In adults with aneurysmal subarachnoid hemorrhage (aSAH), the selective endothelin A receptor antagonist, clazosentan, effectively inhibits the development of symptomatic cerebral vasospasm in CONSCIOUS-2 and REACT clinical trials.4,5) However, cerebral vasospasm treatment for aSAH in children has not yet been established, and the use of clazosentan has not been reported in pediatric cases.1) Therefore, the dosage, pharmacokinetics, and safety of clazosentan in children are not well understood, and extrapolating the evidence from adults to children is limited. This case report demonstrated the safety of an adult dose of clazosentan administered to an adolescent with aSAH.

Case Report

The 14-year-old male was healthy from birth. Regarding family history, his great-uncle had a history of aSAH. The patient was aware of the pulsatile headache 2 weeks before disease onset. He had a severe headache and came to the emergency department of our hospital. At the time of the examination, worsening of impaired consciousness (Glasgow coma scale score: E1V1M4) was observed after vomiting. He had left hemiplegia (Manual Muscle Test 1/5). At admission, the blood test results regarding complement titer, immunoglobulin, and thyroid function showed normal levels. All autoimmune tests (antinuclear antibody, proteinase-3-anti-neutrophil cytoplasmic antibodies, myeloperoxidase antineutrophil cytoplasmic antibody, and anti-Smith antibody) were negative. With the consent of the family, genetic testing for vascular Ehlers–Danlos syndrome, Marfan syndrome, familial aortic aneurysm, and Loeys–Dietz syndrome was performed. Additionally, ultrasound examinations of the neck, heart, and kidneys showed no abnormal findings. Head computed tomography (CT) showed diffuse aSAH with intracerebral hemorrhage in the right frontal lobe, and the patient was diagnosed as World Federation of Neurosurgical Societies (WFNS) grade IV, Fisher group 4 (Figure 1A and B). CT angiography showed a right internal carotid artery terminal aneurysm with a maximum diameter of 2.6 mm (Figure 1C). On the day of onset, an emergency craniotomy was performed. A frontotemporal approach was performed to confirm a saccular aneurysm at the internal carotid artery terminus. Given that no thinning or dissection changes were observed in the vessel wall of the aneurysm, we could perform usual clipping. The right frontal hematoma was then removed to the greatest extent possible. CT angiography on the first day after surgery confirmed the disappearance of the aneurysm inflow and the removal of more than 80% of the hematoma (Figure 2A-C). Considering that this case with intracerebral hematoma presented a high risk for the development of postoperative cerebral vasospasm for WFNS grade IV, Fisher group 4, and that the adolescent had a body almost already developed into adulthood, clazosentan administration was decided after a thorough explanation of the efficacy and complications to his family. For postoperative psychological support, opportunities were provided for the patient to communicate with their parents. Additionally, the importance of cerebral vasospasm treatment was concisely explained to the patient and their family on multiple occasions. Continuous intravenous infusion of clazosentan (10 mg/h, in accordance with the dosage for adult cases) was started on the first day of surgery, and continued until 14 days after symptom onset. Clazosentan was administered alone without the use of fasudil, ozagrel, nimodipine, or cilostazol. According to our hospital's adult protocol for clazosentan administration, fluid management was targeted towards normovolemia with a restriction of the intravenous fluid infusion to under 500 mL, and daily weight measurement and chest radiography were used to assess the presence of fluid retention and pulmonary edema. Due to the patient's reduced oral intake, 1,000 mL of intravenous fluid was administered while withholding enteral nutrition during the period of cerebral vasospasm. Consequently, the fluid balance generally remained between 500 and 1,000 mL. Blood systolic pressure was generally stable between 120 and 135 mmHg, and a vasopressor drug was not required. Body weight ranged between 57 and 59 kg, and creatinine levels remained stable at 0.66 mg/dL. No decrease in saturation of percutaneous oxygen (SpO2) was observed, and clazosentan administration was safely continued without the use of diuretics. Transcranial Doppler (TCD) was not performed, and the occurrence of vasospasm was evaluated using magnetic resonance imaging (MRI) and CT angiography. MRI of the head at 5 and 12 days after surgery showed no cerebral vasospasm or new cerebral infarction (Figure 3A-D). Chest X-rays on the same day did not show pulmonary edema. CT angiography 15 days after surgery also showed no recurrence of aneurysm or new aneurysm (Figure 4). No neurological deterioration suggestive of symptomatic cerebral vasospasm during the administration period was observed. In addition, no adverse events, such as hypotension, pulmonary edema, or cerebral edema, were observed during the administration period. The consciousness disorder and the left hemiplegia gradually improved during the postoperative course. At 30 days after surgery, the patient was discharged with a modified Rankin Scale score of 1. This case report was approved by the Ethics Review Committee of our hospital. Consent was obtained from the patient, whose level of consciousness gradually improved after surgery, and mainly from their parents for treatment and publication.

Figure 1

Admission non-contrast computed topography (CT) demonstrating diffuse subarachnoid hemorrhage with associated right frontal intracerebral hematoma (A, B). Preoperative CT angiography revealing a 2.6-mm saccular aneurysm at the right internal carotid artery terminus (arrow) (C).

Figure 2

Postoperative day 1 computed topography (CT) showing adequate hematoma evacuation (A, B). Postoperative CT angiography confirming complete aneurysm obliteration without parent vessel compromise (arrow) (C).

Figure 3

Magnetic resonance (MR) imaging on postoperative days 5 and 12 demonstrating no evidence of infarction and radiographic vasospasm (A, B; C, D). Diffusion-weighted imaging (A, C) and MR angiography (B, D).

Figure 4

Computed topography (CT) angiography on postoperative day 15 showing no recurrence or formation of new aneurysm.

Discussion

This case report describes the safety of adult-dose clazosentan for cerebral vasospasm after aSAH in adolescent children. This is an exploratory report showing safe practice rather than indicating the effectiveness of clazosentan for cerebral vasospasm after aSAH in children.

In children, aSAH is extremely rare, accounting for 0.5%-4.6% of all brain aneurysms.6) The predominant ages of aSAH in children are 2 years of age and during late adolescence.7) Pediatric cerebral aneurysms are more common in males than females, and the terminal internal carotid artery is the most common location, followed by the middle cerebral artery.8) In addition, although cerebral aneurysms in children might have a different mechanism of occurrence than those in adults and involve infectious, traumatic, and inflammatory factors, most of them are considered idiopathic.2,7) In addition, the fragility of the blood vessel wall and abnormalities of the blood vessel wall matrix can lead to aneurysm formation, and genetic diseases, such as Marfan syndrome and vascular Ehlers–Danlos syndrome, have been reported as causes.2,9) Therefore, in pediatric aSAH cases, genetic analysis is useful for clinical differentiation and risk assessment when vascular connective tissue disease with vascular lesions other than those of the central nervous system is suspected, in addition to family history and physical findings. In this case, no disease associated with the aneurysm was evident on physical findings, blood sampling results, ultrasound examination, and genetic testing. Accordingly, this case was considered to be an aSAH due to idiopathic aneurysm rupture.

Cerebral vasospasm and DCI after aSAH are associated with poor outcomes and their prevention is of clinical importance.10) WFNS, Fisher grade, and intracerebral hematomas are associated with a high risk of cerebral vasospasm after aSAH.3) The highest frequency of cerebral vasospasm in children was reported as 53% using cerebral angiography.1) However, the occurrence of cerebral vasospasm and DCI vary from 21% to 40%, and the evaluation criteria on TCD, catheter angiography, and CT angiography are not uniform.11,12) In addition, the results fluctuate depending on whether clinical symptoms are included in the criteria, and the frequency of cerebral vasospasm vary among reports.1,13) Particularly, the use of CT angiography and angiography in pediatric patients are limited due to invasiveness and radiation exposure.2) Therefore, noninvasive tests (such as MRI and TCD) could present feasible evaluation methods; however, limitations persist owing to the variable expertise of the clinical staff in offering a detailed vasospasm evaluation, child-specific poor acoustic window, and the need for sedation.11) In addition, the pathophysiology of cerebral vasospasm after aSAH in children is poorly understood compared to that in adults.14-18)

In addition to systemic management, such as blood pressure and fluid management, drug therapies, such as nimodipine or fasudil, are widely used in adults for cerebral vasospasm after aSAH.10,19,20) However, cerebral vasospasm treatment protocols vary between facilities, and standardized treatment guidelines have not been established.1) Recently, the CONSCIOUS-2 and REACT trials have shown an inhibitory effect on the onset of symptomatic cerebral vasospasm in adults. However, cerebral vasospasm treatment in children with aSAH has not been established.4,5,21) To date, there are no reports on the use of clazosentan in pediatric patients. Clazosentan is a selective endothelin A receptor antagonist that inhibits cerebral vasospasm development by downregulating the vasoconstriction induced by endothelin-1, whose level rises after aSAH.10) In general, children aged over 12 years are considered physiologically equivalent to adults.22) However, in children under 12 years, clazosentan does not necessarily have the same pharmacological effects or efficacy as in adults because it mainly follows hepatic metabolic pathways and liver clearance is underdeveloped in children, as well as age-related fluctuations in circulating blood volume occur. In addition, the possibility of unknown events that are difficult to predict in adult clinical trials, such as adverse events and drug interactions specific to children during the growth and development processes, cannot be ruled out. In addition, practical and ethical considerations limit conducting pharmacokinetic tests in neonatal and pediatric populations, and the lack of data on the blood levels of clazosentan in children also presents a challenge. Thus, the frequency of onset, pathophysiology, optimal treatment, and pharmacokinetics of cerebral vasospasm in children are unclear. Therefore, the safety and feasibility of adapting the treatment approach used in adults to pediatric cases have not been fully established.

Due to the unavailability of nimodipine in Japan, either fasudil or clazosentan is administered as the standard of care for preventing cerebral vasospasm. However, clear evidence supporting the efficacy of these two agents in pediatric cerebral vasospasm remains insufficient. Nevertheless, based on findings from the RECOVER study showing that clazosentan prevents cerebral vasospasm and DCI more effectively than fasudil, resulting in superior outcomes, clazosentan was selected over conventional drugs such as fasudil, ozagrel, nimodipine, and cilostazol for this case.23) The risk factors for refractory vasospasm, including WFNS grade IV, Fisher group 4, and intracerebral hematoma, were predicted to be extremely high. In addition, since this patient was 14 years old and weighed 60 kg, which was comparable to the weight of an adult patient, it was judged that the evidence on safety from reports in adults was applicable. The dosage of clazosentan was 10 mg/h continuous intravenous infusion (0.18 mg/kg/h body weight) and the duration of administration was 14 days, which was the same as that in the phase III REACT study in adults, were considered safe. Daily weight measurements and chest radiography were performed to evaluate the presence of fluid retention and pulmonary edema, and fluid management was aimed at normovolemia. No adverse events reported in adult trials, such as cerebral edema, were observed. The patient was young and healthy, with high reserve cardiopulmonary and renal functions, which may have contributed to the maintenance of good fluid balance, despite the risk of fluid retention associated with clazosentan administration. In addition, although there are concerns about the progression of cerebral edema in cases of intracerebral hematoma, MRI at 5 and 12 days and CT angiography at 15 days after surgery showed no new or progressive cerebral edema, and clazosentan administration was possible. The fact that intracranial pressure did not increase due to hematoma removal during emergency surgery may have also contributed to ensuring safety in this case. Additionally, no adverse events suggestive of child-specific side effects have been reported in adult clinical trials. As a result, clazosentan could be administered on schedule.

Although this patient had a high risk of cerebral vasospasm, no cerebral vasospasm or DCI was observed on neurological examination, MRI, or CT angiography during the clazosentan administration period. However, since the possibility of the natural course of the disease could not be completely ruled out and quantitative evaluation of cerebral vasospasm with TCD was not performed, the evidence for the efficacy of this drug alone was considered limited.

This clinical report has limitations as it reports a single case; accordingly, the effect of clazosentan administration cannot be compared with the natural disease course, and the effects of surgical treatment, such as hematoma removal, and multimodal treatment, such as appropriate fluid management, cannot be excluded. Notably, microvasospasm was not evaluated using TCD, meaning its occurrence could not be completely ruled out. MRI and CT angiography may fail to detect microischemia and small-diameter vasospasm. In addition, the adult dose may be pharmacokinetically acceptable in late adolescence; however, the optimal dosage according to the developmental stage has not been determined, and the blood levels of clazosentan have not been measured. The pharmacokinetics of clazosentan have not yet been established, and additional cases and pharmacokinetic analyses are essential. Finally, while we evaluated only acute outcomes, we could not evaluate long-term neurocognitive assessments or include observations of long-term neurological development, which are crucial in children.

This report shows that under the premise that the pathogenesis of pediatric cerebral vasospasm is unclear, an adult dose of clazosentan can be safely administered with careful case selection in the context of limited treatment options for aSAH in children, which is a finding of clinical significance. Cases of aSAH in children are rare, and large-scale trials are difficult to conduct. However, the accumulation of case reports and multicenter registries, as well as the establishment of standardized methods for assessing cerebral vasospasm are crucial. This exploratory report suggests the safety and feasibility of administering adult doses of clazosentan in children with cerebral vasospasm after aSAH, and is expected to contribute to the development of future treatment strategies in children.

Conclusion

In this case, the recommended adult dose of clazosentan for aSAH in children was safe. This report suggests that the feasibility and evaluation of pharmacokinetics and additional pediatric cases are important for establishing treatment efficacy.

Conflicts of Interest

All authors have no conflict of interest.

Informed Consent

Informed consent was obtained from the patient.

References
 
© 2026 The Japan Neurosurgical Society

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top